Carbocisteine 5% syrup for adults syrup

Land: Armenien

Språk: engelska

Källa: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiva substanser:

carbocisteine

Tillgänglig från:

Arpimed LLC

ATC-kod:

R05CB03

INN (International namn):

carbocisteine

Dos:

250mg/5ml

Läkemedelsform:

syrup

Enheter i paketet:

glass bottle 120ml

Receptbelagda typ:

OTC

Bemyndigande status:

Registered

Tillstånd datum:

2019-08-15

Produktens egenskaper

SUMMARY PRODUCT CHARACTERISTIC (SPC)
CARBOCISTEINE 5 % SYRUP FOR ADULTS
TRADE NAME– Carbocisteine 5 % syrup for adults
INTERNATIONAL NON-PROPERTY NAME– Carbocisteine
COMPOSITION
Each 5 ml of Carbocisteine 5% syrup for adults contains:
_ACTIVE INGREDIENT:_
carbocisteine - 250 mg;
_INACTIVE INGREDIENTS:_ sodium saccharin, propylene glycol, _
_sucrose, methylparaben,
aroma caramel, sodium hydroxide, color yellow E 110,water purified ._
_
CHEMICAL NAME AND CAS NUMBER
(2R)-2-amino-3-[(carboxymethyl)sulphanyl]propanoic acid
,
2387-59-9.
PHARMACOLOGICAL GROUP AND ATC CODE
Mucolytic agent. ATC code
R05CB03.
PHARMACOLOGICAL ACTION
_Pharmacodynamic properties _
Carbocisteine (S-carboxymethyl L-cysteine) has been shown in normal
and bronchitic animal
models to affect the nature and amount of mucus glycoprotein which is
secreted by the
respiratory
tract.
An
increase
in
the
acid:neutral
glycoprotein
ratio
of
the
mucus
and
a
transformation of serous cells to mucus cells is known to be the
initial response to irritation and
will normally be followed by hypersecretion. The administration of
Carbocisteine to animals
exposed
to
irritants
indicates
that
the
glycoprotein
that
is
secreted
remains
normal;
administration after exposure indicates that return to the normal
state is accelerated. Studies in
humans have demonstrated that Carbocisteine reduces goblet cell
hyperplasia. Carbocisteine can
therefore be demonstrated to have a role in the management of
disorders characterised by
abnormal mucus.
_Pharmacokinetic properties _
Carbocisteineis rapidly absorbed from the gastrointestinal tract, peak
plasma concentrations are
reached after about hour(рН 7-9). Bioavailability is low, less than
10% ,probably, due to the
metabolism in the gastrointestinal tract and "first pass" through the
liver.
Carbocisteine is excreted primarily by the kidneys. The half-life is
about 2 hours.
USES
Violations of bronchial secretions (including acute bronchitis and
acute exacerbations of chronic
diseases of the bronchi and lungs).
DOSAGE AND ADMINIST